查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1857480

依产品类型、治疗类型、最终用户、通路和严重程度分類的血管性血友病治疗市场－2025-2032年全球预测

Von Willebrand Disease Treatment Market by Product Type, Treatment Type, End User, Distribution Channel, Severity - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，血管性血友病治疗市场将成长至 17.5808 亿美元，复合年增长率为 11.82%。

主要市场统计数据
基准年 2024 7.1876亿美元
预计年份：2025年 8.0482亿美元
预测年份：2032年 1,758,080,000 美元
复合年增长率 (%) 11.82%

新的创新、临床重点和持续存在的未满足需求共同塑造了当前血管性血友病治疗模式。

血管性血友病（VWD）的临床和诊疗面临许多复杂挑战，包括患者群体异质性、治疗方法多样以及治疗手段不断更新。临床医师在诊治这种出血性疾病时，必须应对不同的严重程度分级，从轻度血小板黏附缺陷到重度血容量不足，同时还要协调各种干预措施，从按需对症治疗到高风险患者的主动预防。在不同的医疗机构中，医护人员的决策会受到诊断清晰度、个别出血表型、合併症和手术风险等因素的影响，从而形成不同的临床路径，需要灵活的产品策略和协作式医疗模式。

一场革命性的产业变革将透过治疗创新、数位化诊断和整合式照护模式重塑血管性血友病治疗。

血管性血友病（von Willebrand disease）的治疗格局正经历着变革性的转变，这主要得益于治疗、诊断和护理服务等领域的技术创新。在治疗方面，重组替代疗法和标靶止血剂的进步拓展了临床医师的选择范围，尤其凸显了安全性更高、疗效更佳且支持门诊给药的製剂。同时，抗纤溶药物和通道特异性去氨加压素製剂的应用进展，使得围手术全期管理和急性出血事件的处理方法更加精细化。此外，对非因子和基因疗法的持续研究预示着一种更长期的模式转移。

检验2025年美国关税变化对血管性血友病供应链、定价及临床进入管道的累积影响

2025年美国关税调整将为参与血管性血友病治疗的赞助商、经销商和医疗服务提供者的商业决策引入一个新的变数。进口原料、辅助组件和成品生技药品的关税所带来的成本压力可能会波及整个生产过程的经济效益和筹资策略。对于依赖跨境供应链的製造商而言，这可能导致投入成本上升和利润空间收窄，迫使他们重新评估筹资策略以及与供应商和经销商的合约条款。

基于产品、治疗方法、治疗环境、分销管道和疾病严重程度等细分领域的洞察，指南临床策略和准入计划。

在製定血管性血友病（VWD）的临床、商业和准入倡议时，采用细分策略​​至关重要。根据产品类型，治疗方案应考虑去氨加压素、止血剂和替代疗法。去氨加压素可经由鼻内和静脉途径给药；止血剂主要包括氨基己酸和氨甲环酸等抗纤溶药物；替代疗法包括血浆来源和重组VWD因子浓缩物。每种产品类别都有其独特的临床应用、安全性考量和分销需求，这些都会影响其在临床实践中的应用。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 基因疗法在血管性血友病长期治疗的应用日益广泛
  • 发展和临床整合一种半衰期延长的重组血管性血友病因子
  • 在重症患者中扩大使用长效vWF产品的预防性治疗通讯协定
  • 对血管性血友病患者进行药物基因体学学分析，有助于推进个人化治疗策略。
  • 增加对数位化疗法和远端监测解决方案的投资，以追踪出血情况
  • 针对2A型患者体内过量血管性血友病因子所产生的新型RNA干扰药物正在出现
  • 生物相似药治疗血管性血友病因子疗法的引入，给定价和报销框架带来了压力。
  • 快速研究奈米製剂递送平台，以提高血管性血友病药物的稳定性和生物有效性。
  • 越来越重视以儿童患者为中心的护理模式和针对患有血管性血友病的幼年患者的专门治疗方案

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 依产品类型分類的血管性血友病治疗市场

  • 去氨加压素
    • 鼻腔
    • 静脉注射
  • 止血剂
    • 抗纤溶药物
      • 氨基己酸
      • 氨甲环酸
  • 替代疗法
    • 血浆衍生血管性血友病因子浓缩物
    • 重组VWF浓缩物

9. 依治疗类型分類的血管性血友病治疗市场

  • 一经请求
    • 急性治疗
    • 预处理
  • 预防
    • 持续预防
    • 间歇性预防

第十章 依最终用户分類的血管性血友病治疗市场

  • 诊所
    • 门诊部
    • 专科诊所
  • 血友病治疗中心
  • 医院
    • 私立医院
    • 公立医院

第十一章 依分销管道分類的血管性血友病治疗市场

  • 医院药房
  • 网路药房
  • 零售药房
    • 连锁药局
    • 独立药房

第十二章 依严重程度分類的血管性血友病治疗市场

  • 1型
  • 类型 2
    • 2A型
    • 2B型
    • 2M型
    • 2N型
  • 3型

13. 按地区分類的血管性血友病治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的血管性血友病治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国血管性血友病治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • CSL Limited
    • Takeda Pharmaceutical Company Limited
    • Octapharma AG
    • Grifols, SA
    • Laboratoire Francais du Fractionnement et des BIoTechnologies
    • Kedrion SpA
    • Bio Products Laboratory Limited
    • BIoTest AG
Product Code: MRR-B168537791C5

The Von Willebrand Disease Treatment Market is projected to grow by USD 1,758.08 million at a CAGR of 11.82% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 718.76 million
Estimated Year [2025] USD 804.82 million
Forecast Year [2032] USD 1,758.08 million
CAGR (%) 11.82%

Framing the current therapeutic landscape for von Willebrand disease with emerging innovations, clinical priorities, and persistent unmet patient needs

Von Willebrand disease presents a complex clinical and operational challenge that spans a heterogeneous patient population, varied treatment modalities, and an evolving therapeutic toolkit. Clinicians managing this bleeding disorder must navigate distinct severity classifications, from mild platelet adhesion defects through severe quantitative deficiencies, while tailoring interventions that range from symptomatic on-demand therapies to proactive prophylaxis in high-risk patients. Across care settings, provider decision making is influenced by diagnostic clarity, individual bleeding phenotypes, comorbid conditions, and procedural risk profiles, creating diverse clinical pathways that demand adaptable product strategies and coordinated care models.

From a therapeutic perspective, established modalities such as desmopressin, antifibrinolytics, and replacement therapies continue to form the clinical backbone, but recent advances in recombinant biologics and optimized factor concentrates are reshaping treatment algorithms. Diagnostic improvements, including more sensitive assays and genotype-phenotype correlations, are refining patient stratification and informing personalized treatment plans. In parallel, stakeholders across the value chain-clinicians, payers, specialty pharmacies, and hemophilia treatment centers-are recalibrating access criteria and care coordination practices to integrate newer options while preserving safety and cost-effectiveness.

The introduction frames the broader implications of these developments for product development, commercial planning, and clinical adoption. It highlights the need for integrated evidence generation, purposeful stakeholder engagement, and resilient supply models to ensure that therapeutic advances translate into measurable improvements in patient outcomes and equitable access across care settings.

Transformative industry shifts reshaping von Willebrand disease care through therapeutic innovation, digital diagnostics, and integrated care models

The landscape for von Willebrand disease treatment is undergoing transformative shifts driven by innovation across therapeutics, diagnostics, and care delivery. Therapeutically, progress in recombinant replacement therapies and targeted hemostatic agents is expanding clinician options, with attention focused on improved safety profiles, consistent potency, and formulations that support outpatient administration. Concurrently, advances in antifibrinolytic use and route-specific formulations of desmopressin are enabling more nuanced approaches to perioperative management and acute bleeding events, while ongoing research into non-factor and gene-based approaches points to longer-term paradigm shifts.

Diagnostic and monitoring capabilities are evolving in step with therapeutics. Enhanced laboratory assays and standardized functional testing are improving diagnostic accuracy and subtype classification, which in turn permits more individualized treatment algorithms. These diagnostic refinements are increasingly paired with digital tools for bleeding assessment and patient-reported outcome capture, enabling clinicians to measure therapeutic impact more precisely and support pharmacovigilance efforts.

Health system dynamics are also changing. Consolidation among specialty care providers, strengthened networks of hemophilia treatment centers, and payer emphasis on value and outcomes are altering adoption pathways. In response, manufacturers and service providers are investing in real-world evidence, patient support services, and supply chain innovations to differentiate their offerings. Collectively, these shifts are moving the market toward more personalized, value-oriented care models that emphasize durable control of bleeding, improved quality of life, and sustainable access.

Examining the cumulative effects of United States tariff changes in 2025 on von Willebrand disease supply chains, pricing dynamics, and clinical access pathways

The U.S. tariff changes implemented in 2025 introduce a new variable into the operational calculus for sponsors, distributors, and healthcare providers involved in von Willebrand disease therapeutics. Tariff-induced cost pressures on imported raw materials, ancillary components, and finished biologics can reverberate throughout manufacturing economics and procurement strategies. For manufacturers reliant on cross-border supply chains, the result may be elevated input costs and tighter margin dynamics, prompting reassessment of sourcing strategies and contract terms with suppliers and distributors.

Healthcare purchasers and payers are likely to respond by intensifying scrutiny of total cost of care and seeking stronger value demonstration from manufacturers. This can accelerate negotiations on rebates, prior authorization rules, and preferred formulary placements, particularly for high-cost concentrates and specialty products. Providers and clinics operating on thin reimbursement margins may face additional strain if acquisition costs rise, potentially shifting procurement toward cost-stable alternatives or consolidated purchasing through group contracts and integrated delivery networks.

Manufacturers may pursue multiple mitigations, including diversification of supplier bases, strategic inventory buffers, increased use of domestic manufacturing capacity where feasible, and price reconfiguration tied to value agreements. Stakeholders are also assessing the implications for clinical access: changes to procurement economics can affect the availability of certain formulations in outpatient clinics, specialty pharmacies, and hemophilia treatment centers, underscoring the need for proactive contracting, transparent communication with payers, and contingency planning to preserve continuity of care for vulnerable patients.

Segmentation insights aligning product, treatment approach, care settings, distribution routes, and severity types to guide clinical strategy and access planning

A segmentation-aware strategy is essential when designing clinical, commercial, and access initiatives for von Willebrand disease. Based on product type, treatment planning must account for desmopressin, hemostatic agents, and replacement therapies; desmopressin is administered via intranasal and intravenous routes, hemostatic agents are represented primarily by antifibrinolytics including aminocaproic acid and tranexamic acid, and replacement therapies encompass both plasma-derived von Willebrand factor concentrates and recombinant von Willebrand factor concentrates. Each of these product groups carries unique clinical use cases, safety considerations, and distribution needs that influence adoption across care settings.

Based on treatment type, therapeutic pathways differ between on demand and prophylaxis approaches; on demand care includes acute treatment and preprocedural treatment to manage episodic bleeding or procedural risk, while prophylaxis strategies can be implemented as continuous prophylaxis or intermittent prophylaxis to reduce bleeding incidence in patients with recurrent bleeding risk. These treatment typologies inform clinical decision trees and payer criteria, as well as patient education and monitoring programs.

Based on end user, the market interacts with clinics, hemophilia treatment centers, and hospitals; clinics can be further distinguished into outpatient clinics and specialty clinics, and hospitals into private hospitals and public hospitals. Distribution channel considerations reflect hospital pharmacy, online pharmacy, and retail pharmacy models, the latter differentiated into chain pharmacies and independent pharmacies. Based on severity, the disease stratification into Type 1, Type 2, and Type 3, with Type 2 further subtyped into Type 2A, Type 2B, Type 2M, and Type 2N, drives clinical urgency, therapeutic intensity, and monitoring frequency. Integrating these segmentation layers yields nuanced insights for targeting clinical trials, designing patient support services, and optimizing distribution and reimbursement strategies.

Regionally differentiated insights describing demand drivers, infrastructure, regulatory nuances, and patient pathways across Americas, EMEA, and Asia-Pacific healthcare systems

Regional dynamics materially shape therapeutic adoption, regulatory navigation, and delivery models across the three major geographies. In the Americas, established networks of hemophilia treatment centers, a high prevalence of specialty pharmacies, and robust clinical trial activity create an environment where advanced replacement therapies and tailored prophylaxis programs can scale rapidly, provided payers and providers converge on evidence frameworks that demonstrate clinical benefit. Reimbursement mechanisms and state-level procurement policies further influence how therapies are positioned and accessed in ambulatory versus inpatient settings.

In Europe, Middle East & Africa, regulatory pathways and reimbursement environments are heterogeneous, with national health technology assessment processes and centralized or decentralized procurement models affecting market entry and price negotiations. Regional reference pricing, centralized hospital tenders, and a strong emphasis on comparative effectiveness often require manufacturers to present comprehensive real-world and health economic data to achieve uptake, particularly for recombinant and higher-cost products.

In Asia-Pacific, a mix of mature and emerging healthcare systems produces variable adoption patterns. Urban tertiary centers and specialty clinics in higher-income jurisdictions adopt advanced therapeutics and structured prophylaxis programs more rapidly, while broader access in lower-resource settings often depends on public procurement, donor programs, and capacity building within clinics and hospitals. Across all regions, tailored engagement with local clinical networks, alignment with regulatory requirements, and adaptation to distribution infrastructures are necessary to achieve meaningful, sustainable patient access.

Company strategies, pipelines, manufacturing approaches, and partnerships defining the competitive landscape in von Willebrand disease therapeutics

Competitive dynamics in the von Willebrand disease space are driven by a blend of scientific differentiation, manufacturing strategy, and service-oriented offerings. Companies with proprietary recombinant platforms or specialized fractionation capabilities are positioned to emphasize consistent product quality and supply reliability, while firms that pair therapeutics with comprehensive patient support, digital adherence tools, and strong hub services are gaining traction among clinicians and payers seeking predictable outcomes and reduced total cost of care. Investment in regulatory filings and post-approval commitments, including safety surveillance and comparative effectiveness studies, is a recurring strategic theme.

Partnership models-ranging from co-development of next-generation concentrates to distribution alliances with specialty pharmacies and clinical networks-are being used to accelerate access, share development risk, and create integrated care pathways. Manufacturing footprint decisions, including capacity expansions, redundancies, and geographic diversification, reflect a priority on supply resilience, particularly for plasma-derived products that depend on complex sourcing and fractionation processes.

R&D priorities emphasize improving safety margins, extending dosing intervals where clinically appropriate, and generating real-world evidence that substantiates clinical and economic value. Companies that successfully align pipeline priorities with payers' evidence needs and that proactively collaborate with hemophilia treatment centers and professional societies are better positioned to influence care guidelines and adoption patterns in both hospital and outpatient settings.

Actionable recommendations for industry leaders to prioritize clinical innovation, supply resilience, patient-centric access solutions, and strategic collaborations

Industry leaders should prioritize an integrated approach that balances clinical innovation with pragmatic access strategies. First, invest in clinical programs and real-world evidence that demonstrate meaningful patient-centered outcomes, such as reductions in bleeding episodes, improvements in quality of life, and decreased reliance on emergency interventions. This evidence base will be essential to support payer negotiations and formulary inclusion across diverse healthcare systems. Second, build supply chain resilience by diversifying sourcing, establishing strategic inventory buffers, and exploring regional manufacturing options to mitigate tariff and trade-related risks while ensuring continuity of care.

Third, design patient-centric access solutions that cover the continuum from diagnosis to long-term management. This includes supporting diagnostic capacity building, enhancing education for clinicians and patients, and implementing adherence programs that integrate digital monitoring tools. Fourth, engage payers and health technology assessors early to co-develop value frameworks that reflect clinical heterogeneity and real-world resource utilization, enabling more predictable reimbursement pathways. Fifth, cultivate partnerships with hemophilia treatment centers, specialty pharmacies, and clinical networks to streamline distribution, facilitate training, and expedite uptake in both prophylactic and on-demand settings.

Finally, prioritize regulatory and market access planning that anticipates regional nuances, and align commercial strategies with broader public health objectives to support equitable access. By combining scientific differentiation with operational robustness and stakeholder collaboration, industry leaders can convert therapeutic advances into durable improvements in patient care and system-level value.

Rigorous research methodology explaining data sources, analytical frameworks, stakeholder engagement, and validation processes for credible insights

The research underpinning this executive summary uses a mixed-methods approach designed to triangulate evidence and validate practical insights. Primary qualitative work included structured interviews with clinicians, pharmacists, hemophilia treatment center directors, payer representatives, and industry subject-matter experts to capture experiential perspectives on clinical practice, access barriers, and supply chain vulnerabilities. These interviews were complemented by secondary analysis of peer-reviewed clinical literature, regulatory filings, clinical guidelines, and publicly available documentation on therapeutic approvals and safety profiles to ensure clinical accuracy.

Quantitative inputs were derived from aggregated utilization patterns, prescription trends, and distribution channel assessments where publicly accessible, and these were contextualized with clinical trial outcomes and published real-world studies. Analytical frameworks included segmentation mapping, access pathway modeling, and sensitivity assessments of supply-chain disruption scenarios. All analytical outputs were subjected to internal quality control procedures, including data cross-checks, source verification, and methodological peer review by independent clinical and market access advisors.

Limitations of the research are acknowledged and transparently documented; where primary data were limited, findings are presented with appropriate caveats and a focus on directional insights rather than definitive quantification. The methodology emphasizes replicability and transparency, enabling stakeholders to align their own internal analyses with the evidence base presented and to request bespoke extensions that address specific strategic questions.

A concise conclusion synthesizing implications for clinicians, payers, manufacturers, and policy makers to advance care for von Willebrand disease patients

The collective implications of therapeutic innovation, diagnostic refinement, shifting payer expectations, and evolving supply chain dynamics create both opportunities and responsibilities for stakeholders across the von Willebrand disease ecosystem. Clinicians can leverage improved assays and a broader therapeutic toolkit to individualize care and prioritize prophylaxis where clinically warranted, while payers and health systems must balance access with value through evidence-based criteria and outcomes-based contracting. Manufacturers have an imperative to demonstrate clinical benefit, ensure supply reliability, and partner with clinical networks to facilitate appropriate use.

Policy makers and health system leaders should support diagnostic capacity, invest in clinician education, and encourage procurement frameworks that preserve access to essential therapeutics while rewarding innovation that yields patient-centric improvements. Collaborative models that link manufacturers, hemophilia treatment centers, and payers around shared outcome metrics are likely to accelerate the adoption of high-value therapies and improve long-term patient outcomes.

In summary, advancing care for patients with von Willebrand disease will require alignment across scientific development, evidence generation, and commercial execution. When stakeholders pursue coordinated strategies that integrate clinical validity, supply resilience, and equitable access, the potential exists to meaningfully reduce bleeding burden and enhance quality of life for affected patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of gene therapy approaches for long term management of von Willebrand disease
  • 5.2. Development and clinical integration of recombinant von Willebrand factor concentrates with extended half life
  • 5.3. Expansion of prophylactic treatment protocols using extended half life von Willebrand factor products in severe patients
  • 5.4. Advancements in personalized treatment strategies through pharmacogenomic profiling of von Willebrand disease patients
  • 5.5. Growing investment in digital therapeutics and remote monitoring solutions for tracking bleeding episodes
  • 5.6. Emergence of novel RNA interference based agents targeting excessive von Willebrand factor production in type 2A patients
  • 5.7. Pressure on pricing and reimbursement frameworks amid introduction of biosimilar von Willebrand factor therapies
  • 5.8. Surge in research on nanoformulation delivery platforms to enhance von Willebrand factor stability and bioavailability
  • 5.9. Increasing focus on pediatric patient centric care models and specialized regimens for young von Willebrand disease patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Von Willebrand Disease Treatment Market, by Product Type

  • 8.1. Desmopressin
    • 8.1.1. Intranasal
    • 8.1.2. Intravenous
  • 8.2. Hemostatic Agents
    • 8.2.1. Antifibrinolytics
      • 8.2.1.1. Aminocaproic Acid
      • 8.2.1.2. Tranexamic Acid
  • 8.3. Replacement Therapies
    • 8.3.1. Plasma Derived Vwf Concentrates
    • 8.3.2. Recombinant Vwf Concentrates

9. Von Willebrand Disease Treatment Market, by Treatment Type

  • 9.1. On Demand
    • 9.1.1. Acute Treatment
    • 9.1.2. Preprocedural Treatment
  • 9.2. Prophylaxis
    • 9.2.1. Continuous Prophylaxis
    • 9.2.2. Intermittent Prophylaxis

10. Von Willebrand Disease Treatment Market, by End User

  • 10.1. Clinics
    • 10.1.1. Outpatient Clinics
    • 10.1.2. Specialty Clinics
  • 10.2. Hemophilia Treatment Centers
  • 10.3. Hospitals
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals

11. Von Willebrand Disease Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Von Willebrand Disease Treatment Market, by Severity

  • 12.1. Type 1
  • 12.2. Type 2
    • 12.2.1. Type 2A
    • 12.2.2. Type 2B
    • 12.2.3. Type 2M
    • 12.2.4. Type 2N
  • 12.3. Type 3

13. Von Willebrand Disease Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Von Willebrand Disease Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Von Willebrand Disease Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. CSL Limited
    • 16.3.2. Takeda Pharmaceutical Company Limited
    • 16.3.3. Octapharma AG
    • 16.3.4. Grifols, S.A.
    • 16.3.5. Laboratoire Francais du Fractionnement et des Biotechnologies
    • 16.3.6. Kedrion S.p.A.
    • 16.3.7. Bio Products Laboratory Limited
    • 16.3.8. Biotest AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VON WILLEBRAND DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VON WILLEBRAND DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VON WILLEBRAND DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY AMINOCAPROIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY AMINOCAPROIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY AMINOCAPROIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY AMINOCAPROIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY AMINOCAPROIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY AMINOCAPROIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TRANEXAMIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TRANEXAMIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TRANEXAMIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TRANEXAMIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TRANEXAMIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TRANEXAMIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PLASMA DERIVED VWF CONCENTRATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PLASMA DERIVED VWF CONCENTRATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PLASMA DERIVED VWF CONCENTRATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PLASMA DERIVED VWF CONCENTRATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PLASMA DERIVED VWF CONCENTRATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PLASMA DERIVED VWF CONCENTRATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT VWF CONCENTRATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT VWF CONCENTRATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT VWF CONCENTRATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT VWF CONCENTRATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT VWF CONCENTRATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RECOMBINANT VWF CONCENTRATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PREPROCEDURAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PREPROCEDURAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PREPROCEDURAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PREPROCEDURAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PREPROCEDURAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PREPROCEDURAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CONTINUOUS PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CONTINUOUS PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CONTINUOUS PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CONTINUOUS PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CONTINUOUS PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CONTINUOUS PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTERMITTENT PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTERMITTENT PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTERMITTENT PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTERMITTENT PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTERMITTENT PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INTERMITTENT PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2A, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2A, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2A, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2A, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2A, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2A, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2M, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2M, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2M, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2M, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2M, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2M, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2N, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2N, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2N, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2N, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2N, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2N, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 3, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY REPLACEMENT THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY ON DEMAND, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY TYPE 2, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA VON WILLEBRAND DISEASE TREATMENT MARKET SIZE, BY HEMOSTATIC AGENTS, 2018-2024 (USD MILLION)